Received Mar 13, 2026
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| TDAP | TDAP (NO BRAND NAME) | UNKNOWN MANUFACTURER | UNK | FY293 | — |
Full body rash; This non-serious case was reported by a other health professional and described the occurrence of generalized rash in a 11-year-old female patient who received DTPa (Reduced antigen) (Tdap Vaccine) (batch number FY293, expiry date 23-JUN-2028) for prophylaxis. On 02-MAR-2026, the patient received Tdap Vaccine. On 05-MAR-2026, 3 days after receiving Tdap Vaccine, the patient experienced generalized rash (Verbatim: Full body rash). The outcome of the generalized rash was not resolved. It was unknown if the reporter considered the generalized rash to be related to Tdap Vaccine. It was unknown if the company considered the generalized rash to be related to Tdap Vaccine. Additional Information: GSK Receipt Date: 06-MAR-2026 The case has been linked with case US2026031121, reported by same reporter. The batch number was not provided and a request for this information has been made.; Sender's Comments: US-GSK-US2026031121:SAME REPORTER